Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cariboo Gold History Inspires Modern Discovery (CSE:GCC) (OTC:GCCFF) (click to learn more) Southern Energy Corp. Completes US$23.5 Million Financings and Royalty Sale (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Harmony Biosciences Holdings Inc HRMY

Healthcare Biotechnology
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops... see more

Recent & Breaking News (NDAQ:HRMY)

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

Business Wire 20 hours ago

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Business Wire 7 days ago

Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Business Wire January 7, 2026

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

Business Wire December 8, 2025

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Business Wire December 2, 2025

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

Business Wire November 24, 2025

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

Business Wire November 19, 2025

Harmony Biosciences to Participate in Upcoming Investor Conferences

Business Wire November 18, 2025

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

Business Wire November 4, 2025

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

Business Wire October 23, 2025

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

Business Wire September 24, 2025

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

Business Wire August 26, 2025

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

Business Wire August 21, 2025

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

Business Wire August 5, 2025

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

Business Wire July 22, 2025

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

Business Wire July 15, 2025

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

Business Wire June 11, 2025

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

Business Wire June 5, 2025

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Business Wire June 4, 2025

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

Business Wire May 6, 2025

Podcasts